Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pegylated recombinant human hyaluronidase PH20
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
S1313, Combination Chemotherapy with or without PEGPH20 in Treating Patients with Newly Diagnosed Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1313, NCI-2013-01776, PS1313_A09PAMDREVW01, NCT01959139
PEGPH20, Gemcitabine Hydrochloride, and Nab-Paclitaxel in Treating Patients with Borderline Resectable Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 144515, NCI-2015-01213, 121697, NCT02487277
Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HALO-107-101, NCI-2015-01789, NCT02563548
PEGPH20 and Cetuximab before Surgery in Treating Patients with Pancreatic Cancer That Can Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14-039, NCI-2014-01977, NCT02241187
Gemcitabine Hydrochloride, Nab-paclitaxel, PEGPH20, and Rivaroxaban in Treating Patients with Stage III-IV Pancreatic Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 16-1066, NCI-2016-01542, NCT02921022
Start Over